SG11202111773QA - Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity - Google Patents
Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunityInfo
- Publication number
- SG11202111773QA SG11202111773QA SG11202111773QA SG11202111773QA SG11202111773QA SG 11202111773Q A SG11202111773Q A SG 11202111773QA SG 11202111773Q A SG11202111773Q A SG 11202111773QA SG 11202111773Q A SG11202111773Q A SG 11202111773QA SG 11202111773Q A SG11202111773Q A SG 11202111773QA
- Authority
- SG
- Singapore
- Prior art keywords
- polymorph
- pain
- polymorphic form
- treatment
- inflammation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19153315 | 2019-01-23 | ||
| PCT/EP2020/051528 WO2020152226A1 (en) | 2019-01-23 | 2020-01-22 | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111773QA true SG11202111773QA (en) | 2021-11-29 |
Family
ID=65228356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111773QA SG11202111773QA (en) | 2019-01-23 | 2020-01-22 | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11891350B2 (https=) |
| EP (1) | EP3860582B1 (https=) |
| JP (2) | JP7611148B2 (https=) |
| KR (1) | KR20210119403A (https=) |
| CN (1) | CN113329746B (https=) |
| AU (1) | AU2020210831B2 (https=) |
| BR (1) | BR112021019476A2 (https=) |
| CA (1) | CA3118996A1 (https=) |
| DK (1) | DK3860582T3 (https=) |
| ES (1) | ES2913977T3 (https=) |
| IL (1) | IL282718B2 (https=) |
| PL (1) | PL3860582T3 (https=) |
| PT (1) | PT3860582T (https=) |
| RS (1) | RS63270B1 (https=) |
| SG (1) | SG11202111773QA (https=) |
| WO (1) | WO2020152226A1 (https=) |
| ZA (1) | ZA202107346B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3939578A1 (en) * | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
| WO2026037478A1 (en) | 2023-08-11 | 2026-02-19 | Novaremed AG | (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7642290B2 (en) | 2002-10-03 | 2010-01-05 | Novaremed Limited | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| JP4939396B2 (ja) * | 2004-03-26 | 2012-05-23 | ノヴァレメッド リミテッド | Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法 |
| GB0804213D0 (en) | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| CN102821761B (zh) * | 2009-09-09 | 2015-06-10 | 诺瓦麦有限公司 | 用于治疗疼痛和炎症的n-取代的苯丙酰胺或苯丙烯酰胺 |
| US8802734B2 (en) | 2009-09-09 | 2014-08-12 | Novaremed Limited | Method of treating or preventing pain |
| GB0916073D0 (en) | 2009-09-14 | 2009-10-28 | Cintec Int Ltd | Improvements in and relating to building anchor systems |
| AU2012348529B2 (en) | 2011-12-08 | 2017-03-30 | Novaremed Ltd. | Isolated stereoisomeric forms of (S) 2-N (3-O-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide |
-
2020
- 2020-01-22 US US17/295,788 patent/US11891350B2/en active Active
- 2020-01-22 EP EP20703152.7A patent/EP3860582B1/en active Active
- 2020-01-22 PT PT207031527T patent/PT3860582T/pt unknown
- 2020-01-22 BR BR112021019476A patent/BR112021019476A2/pt unknown
- 2020-01-22 KR KR1020217023524A patent/KR20210119403A/ko not_active Ceased
- 2020-01-22 AU AU2020210831A patent/AU2020210831B2/en active Active
- 2020-01-22 ES ES20703152T patent/ES2913977T3/es active Active
- 2020-01-22 WO PCT/EP2020/051528 patent/WO2020152226A1/en not_active Ceased
- 2020-01-22 CN CN202080010393.8A patent/CN113329746B/zh active Active
- 2020-01-22 JP JP2021543276A patent/JP7611148B2/ja active Active
- 2020-01-22 DK DK20703152.7T patent/DK3860582T3/da active
- 2020-01-22 IL IL282718A patent/IL282718B2/en unknown
- 2020-01-22 SG SG11202111773QA patent/SG11202111773QA/en unknown
- 2020-01-22 CA CA3118996A patent/CA3118996A1/en active Pending
- 2020-01-22 RS RS20220510A patent/RS63270B1/sr unknown
- 2020-01-22 PL PL20703152.7T patent/PL3860582T3/pl unknown
-
2021
- 2021-09-23 ZA ZA2021/07346A patent/ZA202107346B/en unknown
-
2024
- 2024-12-23 JP JP2024226332A patent/JP2025036479A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020210831B2 (en) | 2025-02-13 |
| ZA202107346B (en) | 2023-10-25 |
| JP7611148B2 (ja) | 2025-01-09 |
| PL3860582T3 (pl) | 2022-08-01 |
| ES2913977T3 (es) | 2022-06-07 |
| DK3860582T3 (da) | 2022-05-23 |
| IL282718B1 (en) | 2024-04-01 |
| KR20210119403A (ko) | 2021-10-05 |
| EP3860582A1 (en) | 2021-08-11 |
| US11891350B2 (en) | 2024-02-06 |
| IL282718B2 (en) | 2024-08-01 |
| CA3118996A1 (en) | 2020-07-30 |
| AU2020210831A1 (en) | 2021-05-20 |
| JP2025036479A (ja) | 2025-03-14 |
| CN113329746A (zh) | 2021-08-31 |
| RS63270B1 (sr) | 2022-06-30 |
| JP2022518288A (ja) | 2022-03-14 |
| IL282718A (en) | 2021-06-30 |
| WO2020152226A1 (en) | 2020-07-30 |
| PT3860582T (pt) | 2022-07-08 |
| CN113329746B (zh) | 2025-05-02 |
| BR112021019476A2 (pt) | 2021-11-30 |
| EP3860582B1 (en) | 2022-05-04 |
| US20220002228A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5371790B2 (ja) | 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、５−ｈｔ３および５−ｈｔ１ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジン | |
| JP5603244B2 (ja) | Ｓｅｒｔ、５−ｈｔ３および５−ｈｔ１ａの組み合わせた活性を有する化合物の治療的使用 | |
| JP5921539B2 (ja) | 下肢静止不能症候群を治療する方法 | |
| JP2025036479A (ja) | 疼痛、炎症および／または自己免疫の処置または予防における使用のための化合物 | |
| TWI441630B (zh) | 曲馬朵（Ｔｒａｍａｄｏｌ）和可舒葆（Ｃｏｘｉｂ）之共結晶物 | |
| EP2475361B1 (en) | N-substituted benzenepropanamides for use in the treatment of pain and inflammation | |
| HK40061961B (en) | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | |
| HK40061961A (en) | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | |
| WO2026037478A1 (en) | (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain | |
| WO2014164784A1 (en) | Hdac inhibitor polymorphic forms and methods of use | |
| HK1173380B (en) | Co-crystals of tramadol and coxibs |